Potential of -Adrenoceptor Agonists as Add-On Therapy for Multiple Sclerosis: Focus on Salbutamol (Albuterol)

Author： Makhlouf K.   Weiner H.L.   Khoury S.J.  

Publisher： Adis International

ISSN： 1172-7047

Source： CNS Drugs, Vol.16, Iss.1, 2002-01, pp. : 1-8

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Potential Use of Modulators of Oxidative Stress as Add-on Therapy in Patients with Anxiety Disorders

By  

Current Drug Targets, Vol. 19, Iss. 6, 2018-04 ,pp. : 636-650

Bentham Science Publishers

Access to resources Recommend Favorite

Peroxisome Proliferator-Activated Receptor Agonists as Potential Therapeutic Agents in Multiple Sclerosis

By  

Mini Reviews in Medicinal Chemistry, Vol. 7, Iss. 11, 2007-11 ,pp. : 1129-1135

Bentham Science Publishers

Access to resources Recommend Favorite

Statins and their potential targets in multiple sclerosis therapy

By Stüve Olaf   Prod’homme Thomas   Slavin Anthony   Youssef Sawsan   Dunn Shannon   Steinman Lawrence   Zamvil Scott S  

Expert Opinion on Therapeutic Targets, Vol. 7, Iss. 5, 2003-10 ,pp. : 613-622

Informa Healthcare

Access to resources Recommend Favorite

3 -Adrenoceptor agonists: potential, pitfalls and progress

By Arch J.R.S.  

European Journal of Pharmacology, Vol. 440, Iss. 2, 2002-04 ,pp. : 99-107

Elsevier

Access to resources Recommend Favorite

Cost Effectiveness of Leukotriene Receptor Antagonists versus Long-Acting Beta-2 Agonists as Add-On Therapy to Inhaled Corticosteroids for Asthma: A Pragmatic Trial

By Wilson Edward C.F.  

PharmacoEconomics, Vol. 28, Iss. 7, 2010-07 ,pp. : 597-608

Adis International

Access to resources Recommend Favorite